Ignite Creation Date:
2025-12-24 @ 11:36 PM
Ignite Modification Date:
2026-01-10 @ 5:18 PM
Study NCT ID:
NCT05659056
Status:
RECRUITING
Last Update Posted:
2024-04-16
First Post:
2022-12-02
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-11-29
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-07
Completion Date Type:
ESTIMATED
First Submit Date:
2022-12-02
First Submit QC Date:
None
Study First Post Date:
2022-12-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-14
Last Update Post Date:
2024-04-16
Last Update Post Date Type:
ACTUAL